ANYA BIOPHARM INC.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
ORAL PEPTIDE
Summary of development timelines-product
MIRA/JE® Design
Lead Optimization
Preclinical Studies
Phase I
Phase II
Phase III
ANY002 Oral GLP1 product A: Prototype with human PK results available
ANY004 Oral GLP1 product B: Prototype in animal st
Summary of development timelines-product
MIRA/JE® Design
Lead Optimization
Preclinical Studies
Phase I
Phase II
Phase III
ANY002 Oral GLP1 product A: Prototype with human PK results available
ANY004 Oral GLP1 product B: Prototype in animal st
Founded Year
2016
Unified Business No.
66262721
Status
Active
Number of Employees
15
Total Paid-in
Capital
491,015,200 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2025)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Anya is a young, agile and innovative publicly listed (TWO: 7776) pharmaceutical company founded in Taipei, Taiwan with offices in India and the United States. Our core mission is to be the authority in oral delivery of peptides. Our patented technology platform Mira/Je® is a flexible solution easy to adapt to a large variety of peptides. Mira/Je® has shown delivery of therapeutic amount in a number of clinical and preclinical studies in a variety of peptides such as teriparatide, leuprorelin, octreotide, semaglutide, liraglutide, tirzepatide and insulin glargine.
The management team has extensive experience in the pharmaceutical industry with average 20 years in development and commercialization of biologics and small molecules.
Our guiding principles are Excellence, Engagement and Efficiency.
The management team has extensive experience in the pharmaceutical industry with average 20 years in development and commercialization of biologics and small molecules.
Our guiding principles are Excellence, Engagement and Efficiency.
